Inpharma 1578 - 10 Mar 2007

1

Encephalitis vax: single dose holds its own against 3-dose version A single-dose vaccine against Japanese encephalitis [ChimeriVax-JE]* compares favourably with the licensed three-dose vaccine [Je-Vax], according to the results of a phase III efficacy trial. 820 participants were randomised 1:1 to inoculation with the single- or the three-dose vaccine, in a doubledummy fashion. At 30 days after the last inoculation, the primary endpoint of seroconversion was achieved in 99.1% of single-dose vaccine recipients, a significantly greater proportion than that in the three-dose recipients (74.8%). Moreover, 93.6% of single-dose recipients achieved seroconversion by 14 days postinoculation. There were no serious vaccine-associated adverse events over the 60-day treatment observation period. The single-dose vaccine was associated with a significantly lower incidence of local injection-site reactions, compared with the three-dose vaccine. * Acambis; phase III in the US, India and Australia Acambis plc. Acambis’ JE vaccine meets and exceeds primary endpoint in pivotal Phase 3 efficacy trial. Media Release : 1 Mar 2007. Available from: URL: http:// 809073093 www.acambis.com

1173-8324/10/1578-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Inpharma 10 Mar 2007 No. 1578